fda enforcement actions bpc-157 FDA's own advisory committee voted 8-6 Thursday. BPC-157, on the compounding list now, for ulcerative colitis. staff argued against it, laid out the data gaps, the whole case. Panel overruled them An FDA advisory committee voted

Clinical Update 11/09/2019 Choline Concern A large study found that people with higher intakes of choline from their diets had a higher risk of death, specifically cardiovascular death, than people with lower choline intakes

We serve clients from Northglenn CO, Commerce City CO, Denver CO, Lafayette CO, Monument CO, Colorado Springs CO, Falcon CO, Castle Rock CO, and surrounding areas

semaglutide: clinical decision-making in the GLP-1 landscape Tirzepatide Versus Semaglutide on Weight Loss in Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis of Direct Comparative Studies Tirzepatide: A Systematic Update Efficacy and safety of tirzepatide, dual GLP-1/GIP receptor agonists, in the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials Tirzepatide, a dual GIP/GLP-1 receptor agonist, alleviates metabolic dysfunction-associated steatotic liver disease by reducing the expression of CD36 and OBP2A

Dysregulation of peptide hormones contributes to conditions such as gastroparesis, inflammatory bowel disease, and malabsorption syndromes

BPC-157 is a synthetic fragment of a naturally occurring peptide found in human gastric juice, made up of 15 amino acids